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Results: The resistance indexes of A549/Gem and H460/Gem are 
stably about 120 respectively which had exceeded 160 before had 
acquired steady gemcitabine resistance in the process of inducement. 
Expression of CDA, RRM1, PTEN and ERCC1 varies according to the 
changing trend of resistance indexes of gemcitabine, but expression of 
dCK does not change apparently. Since wild type promoter can amplify 
the frequency of genome in different derivational stages of A549/Gem 
and H460/Gem, but allelotype not, the gene type of A549/Gem, H460/
Gem and their parental cells are still wild type. 
Conclusion: Compared with their parental cells, expression of CDA, 
RRM1, PTEN and ERCC1 in human gemcitabine-resistant non-small 
cell lung cancer cell lines A549/Gem and H460/Gem rise, and dCK 
change is not obvious; the gene type of them are all wild type.
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Background: To establish human gemcitabine-resistant non-small cell 
lung cancer cell lines and discuss their biological characters so as to 
elaborate the possible mechanisms of gemcitabine resistance. 
Methods: Two human Gemcitabine-Resistant non-small cell lung can-
cer cell lines A549/Gem and H460/Gem were established by repeated 
clinical serous peak concentration then low but gradually increasing 
concentration of gemcitabine and 2/3 clinical serous peak concentration 
gemcitabine intermittent selection from their parental cells human lung 
adenocarcinoma cell line A549 and human large cell lung cancinoma 
cell line NCI-H460 who are sensitive to gemcitabine respectively. 
During the course of inducement, we had monitored their morphol-
ogy, checked their resistance indexes and resistant pedigree by MTT 
method, gathered their growth curves and calculated their doubling 
time, examined their DNA contents and cell cycles by FCM; at the 
same time, we had measured their expression of P53, EGFR, c-erb-B-2, 
PTEN, PCNA, c-myc, VEGF, MDR-1, Bcl-2, nm23, MMP-9, TIMP-1 
and CD44v6 Proteins. 
Results: The resistance indexes of A549/Gem and H460/Gem to 
gemcitabine are 1.644 and 129.783, respectively, and the cell lines 
also exhibits respectively cross-resistance to vinorelbine, docetaxel, 
etoposide, cisplatin and taxol, etoposide, cisplatin. Compared with their 
parental cells, A549/Gem and H460/Gem are mixed with giant cells of 
different sizes that are larger and more irregular. The doubling time of 
A549/Gem is shorter and ﬁgures in G0-G1 phase are increased. Mean-
while, H460/Gem have developed contrary changes. Furthermore, they 
produced different results in different checkpoints. The farther studies 
indicated that compared with A549, PTEN expression of A549/Gem 
had been (-) and then rises, MMP-9 expression rises, EGFR TIMP-1 
and c-myc (+), P53 c-erb-B-2 and bcl-2 drops, nm23 rises and then (-), 
and PCNA, MDR-1 (-). Compared with NCI-H460, H460/Gem had ex-
hibited TIMP-9 (+) and P53 CD44v6 (-), then c-erb-B-2 (+), increased 
expression of nm23 bcl-2 MDR-1 and decreased expression of MMP-9 
VEGF P53. 
Conclusion: The human gemcitabine-resistant non-small cell lung 
cancer cell lines A549/Gem and H46/Gem have achieved multi-drug 
resistance and great changes of biological characters compared with 
their parental cells. And these changes possibly participate in the for-
mation of multidrug resistance.
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Background: Disseminated cancer cells may initially require local 
nutrients and growth factors to thrive and survive in bone marrow be-
fore developing into overt metastasis. Bone seems a milieu particularly 
favorable for the growth, vascularization and survival of lung cancer. 
In order to explore the mechanism how bone stromal factors contribute 
to the bone tropism, we therefore use serum of bone marrow aspiration 
(BM) and condition medium from bone stromal cells(BSC) to study 
their effects on lung cancer cells. 
Materials and Methods: Lung cancer cell lines, A549, H460, gastric 
cancer cell line SGC-7901 were obtained originally from ATCC. SPC-
A1 lung cancer cell line, tong cancer cell line T8113 and primary bone 
stromal cells were established in our lab before, and reported in many 
publications. These cells were cultured in pheno- red -free DMEM / 
10% fetal calf serum. Regular medium(RM), condition medium from 
ﬁbroblast cell(FC) were chosen as controls. MTT assay was applied to 
analyze these different treatments on proliferation of lung cancer cells 
and controls. Flow cytometry analysis of DNA content was performed 
to assess the cell cycle phase distribution using propidium iodide ﬂuo-
rescence. Adhesion assay was used to compare cells adhesion on the 
plates coated with different medium. 
Results: (1) In our cancer center, disseminated cancer cells were found 
in 35% lung cancer patients, 41.7% breast cancer patients, and 39.6% 
gastric cancer patients. Bone metastasis was often in breast/lung cancer 
patients, but very rare in gastrointestinal cancer patients. (2) Both su-
pernatants from BM and BSC signiﬁcantly increased the proliferation 
of H460 lung cancer cells, which had widespread skeletal metastatic 
potential Yang M, Cancer Res. 1998). This activity was not shown in 
A549 and SPC-A1 lung caner cells, which had low bone metastasis 
potential according to literal reports and our animal study. BM did 
not improve the proliferation of tong cancer cells T8113, which had 
very low bone metastasis potential, and even inhibited the growth of 
SGC7901 gastric cancer cells. (3) Bone- stromal- cell- induced prolifer-
ation in H460 cells was blocked by Zometa (biphosphanate), but not by 
PI3-K inhibitor Wartmannin in time-course and doze dependent studies. 
(4)BM and BSC also induced cell cycle progression in H460 cells, but 
not A549 and SPC-A1 cells shown by ﬂow cytometry. (5) Some factors 
literally related to bone metastasis were compared. ELISA showed the 
levels of TGF-b, HGF, IGF-1, IL-6 and PDGF were identical in BM, 
BSC, RM and FC. (6) Similar numbers of H460 cells adhered to BM, 
BSC and RM coated plates. There were also no signiﬁcant difference 
for SPC-A1 and A549 cells in adhesion capability to different medium. 
Conclusion: Although a supporting role of bone stromal factors on 
metastatic breast or prostate cancer cells have been repeatedly pro-
posed, it is largely unknown the mechanism of bone tropism for lung 
cancer. In our study, we found bone stromal factors favored the growth 
of cancer cells with bone tropism by increasing proliferation, cell cycle 
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progression, but not adhesion capability. Bone stromal cells should 
secret some growth factors although not identiﬁed by ELISA, which 
promoted the proliferation of high bone metastasis potential cells. The 
high through-out assay, 2D gel followed by mass spectromics, is cur-
rently ongoing to recognize the effective factors. 
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There is a clear need to develop effective chemoprevention strategies 
to reduce the high incidence of lung cancer. The purpose of this study 
was to evaluate the effectiveness of two targeted approaches, reversal 
of gene silencing through demethylation therapy and the induction of 
apoptosis through activation of the PPAR-γ pathway. A chemopreven-
tion study was designed in which A/J mice, which are highly suscep-
tible to lung cancer, were treated with the tobacco carcinogen NNK. 
Animals were held for 42 weeks to allow the development of pre-inva-
sive lesions: alveolar hyperplasias and adenomas. Then were separated 
into 12 groups of 15 mice and treated for 6 weeks with individual 
or a combination of the agents [hydralazine (Hyd), selenium (Se), 
sodium phenylbutyrate (PheB), valproic acid (VPA), iloprost (Ilo), and 
rosiglitazone (Ros)]. Following sacriﬁce, the number of lesions was 
determined for each animal by evaluating H&E stained sections that 
included all lung lobes. Lesions were classiﬁed as hyperplasia, ad-
enoma, or carcinoma. The most dramatic effects on tumor progression 
were seen in the groups in which Ros was administered. The number of 
hyperplasias increased by 52%, while the number of adenomas was de-
creased by 31% (p < 0.05) with Ros treatment alone compared to sham. 
The combination of Ros with Se, Hyd, and PheB resulted in a decrease 
in adenomas by 38%. The area and volume of hyperplasias and adeno-
mas from sham and treatment groups were then quantiﬁed. Volume of 
the hyperplasias and adenomas decreased by 42% and 67%, respec-
tively (p < 0.005) in the combination therapy group. Additionally, a 
companion study using nude mice was also under-taken to evaluate the 
effects of Ros on tumor growth rates. In this study 72 nude mice were 
divided into 4 groups of 18 mice and inoculated with one of 4 cancer 
cell lines (IO33, CL25, H23, and H125). Within these groups the mice 
were divided into 6 sub-groups of 3 mice each according to treatment 
plans (Sham, Se, Ros, PheB, Ros+PheB, and Ros+PheB+Hyd). Tumor 
growth, in terms of total area of tumors, for each sub-group was charted 
over a 4 week period after which the mice were sacriﬁced. Preliminary 
statistical studies have already shown high degree of correlation with 
our previous work. Of note is that within the H125 cell line; the combi-
nation of Ros+PheB retards the progression of tumor growth compared 
to sham with a difference in average total area of -286 mm2 (p< 0.02; 
CI: -513.3 to -58.7 mm2). These studies provide a strong indication that 
Ros treatment alone and in combination with PheB can dramatically 
affect lung tumor development by blocking the progression of hyper-
plasias to adenomas and through affecting the clonal expansion of these 
lesions. These ﬁndings could ultimately lead to a new chemoprevention 
strategy for lung cancer. (Supported by a fellowship from IASLC).
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Background: Development of molecularly targeted kinase inhibi-
tors against epidermal growth factor receptor (EGFR) represents a 
major therapeutic advance in treatment of non-small cell lung cancer 
(NSCLC). Kinase domain mutations of the EGFR gene, most com-
monly L858R (exon 21) and short in-frame deletions in exon 19, have 
been shown to confer general sensitivity towards the EGFR kinase 
inhibitors geﬁtinib and erlotinib. Other less frequently identiﬁed muta-
tions are much less well characterized. We recently described a unique 
somatic mutation, E884K (exon 22), that occurred in combination with 
the L858R mutation (L858R+E884K) in a patient with erlotinib-refrac-
tory stage IV NSCLC. This patient’s leptomeningeal metastases had a 
striking response to geﬁtinib monotherapy. We hypothesized that EGFR 
kinase mutations can work in concert to differentially alter kinase 
inhibitor sensitivity and downstream signaling. 
Method: We generated transfects of Cos-7 cells expressing the follow-
ing mutant EGFR constructs for signaling and kinase inhibition studies: 
(1) wild type, (2) L858R, (3) E884K, (4) L858R+E884K and (5) 
L858R+R958D. Standard phospho-immunoblotting with phosphospe-
ciﬁc antibodies was used in to study mutant EGFR signaling in vitro. 
EGFR kinase inhibition studies were performed with the EGFR vari-
ants using erlotinib, geﬁtinib and dual EGFR/ERBB2 small molecule 
inhibitors. Molecular modeling and bioinformatics sequence analysis 
was performed to understand the structural mechanism of the effect of 
E884K-EGFR.
Results: We show that E884K worked in concert with L858R and al-
tered sensitivity to kinase inhibitors and mutant receptor signaling. Mu-
tation of E884 to lysine disrupts an ion pair with residue R958 in the 
EGFR kinase domain C-lobe, an interaction that is highly conserved 
within the human kinome, many of which are “druggable targets”, 
demonstrated by our sequence analysis and structural modeling. When 
in cis with L858R, the E884K-EGFR mutation desensitized, in a domi-
nant fashion, the mutant receptor to erlotinib, while further sensitizing 
the receptor to geﬁtinib and an EGFR/ERBB2 dual inhibitor with cor-
responding inhibition of p-EGFR and downstream signaling inhibition 
of p-AKT and p-STAT3. Inhibitor sensitivity modulation similar to that 
seen with E884K was observed with the R958D mutation that should 
also disrupt the conserved ion pair. Both alone and in cis, the E884K 
mutation was activating with speciﬁc cellular phosphoproteome activa-
tion pattern and downstream signaling regulation distinct from that of 
L858R alone. 
Conclusion: E884K-EGFR mutation worked in concert with L858R 
in cis to differentially alter sensitivity to speciﬁc kinase inhibitors and 
selective downstream phosphoproteomic signaling activation. Our ﬁnd-
ings suggest that mutations of the conserved ion pair E884-R958 may 
result in conformational changes that alter kinase substrate recognition. 
